Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993 Oct;34(10):1351–1356. doi: 10.1136/gut.34.10.1351

Somatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues.

G V Miller 1, S R Preston 1, L F Woodhouse 1, S M Farmery 1, J N Primrose 1
PMCID: PMC1374540  PMID: 7902309

Abstract

This study characterises the somatostatin binding site in human gastrointestinal cancer and mucosa in terms of cationic specificity and relative affinity for three somatostatin analogues. Competitive displacement assays were performed on plasma membranes from human gastric and colonic tissues using radiolabelled somatostatin-14 as ligand. Comparison was made with the somatostatin binding site in rat cerebral cortex. In gastrointestinal tissue, magnesium decreased and sodium increased specific binding. By contrast, in rat cerebral cortex, the converse cationic effect was seen. These changes resulted from alterations in receptor density, with no change in receptor affinity. Displacement studies were then performed with somatostatin-14 and somatostatin analogues RC-160, somatuline, and octreotide. RC-160 and somatuline displaced radiolabel from binding sites in gastric and colonic cancer and mucosa with 10-fold lower affinity than the native peptide. Octreotide did not displace radioligand in gastric or colonic cancer at any concentration tested. By contrast, in rat cortex, although all three analogues displaced with a lower affinity than the native peptide, there was no difference between analogues. These data suggest a distinct somatostatin receptor subtype in gastrointestinal tissues.

Full text

PDF
1351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  2. Czernik A. J., Petrack B. Somatostatin receptor binding in rat cerebral cortex. Characterization using a nonreducible somatostatin analog. J Biol Chem. 1983 May 10;258(9):5525–5530. [PubMed] [Google Scholar]
  3. Gorden P., Comi R. J., Maton P. N., Go V. L. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989 Jan 1;110(1):35–50. doi: 10.7326/0003-4819-110-1-35. [DOI] [PubMed] [Google Scholar]
  4. Klijn J. G., Hoff A. M., Planting A. S., Verweij J., Kok T., Lamberts S. W., Portengen H., Foekens J. A. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer. 1990 Oct;62(4):627–630. doi: 10.1038/bjc.1990.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Konturek S. J., Bilski J., Jaworek J., Tasler J., Schally A. V. Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion. Proc Soc Exp Biol Med. 1988 Feb;187(2):241–249. doi: 10.3181/00379727-187-42661. [DOI] [PubMed] [Google Scholar]
  6. Lamberts S. W., Koper J. W., Reubi J. C. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest. 1987 Aug;17(4):281–287. doi: 10.1111/j.1365-2362.1987.tb02188.x. [DOI] [PubMed] [Google Scholar]
  7. Maton P. N., Gardner J. D., Jensen R. T. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci. 1989 Mar;34(3 Suppl):28S–39S. doi: 10.1007/BF01536043. [DOI] [PubMed] [Google Scholar]
  8. Meyers C. A., Coy D. H., Murphy W. A., Redding T. W., Arimura A., Schally A. V. [Phe4]somatostatin: a potent, selective inhibitor of growth hormone release. Proc Natl Acad Sci U S A. 1980 Jan;77(1):577–579. doi: 10.1073/pnas.77.1.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Miller G. V., Farmery S. M., Woodhouse L. F., Primrose J. N. Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br J Cancer. 1992 Aug;66(2):391–395. doi: 10.1038/bjc.1992.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  11. Parmar H., Bogden A., Mollard M., de Rougé B., Phillips R. H., Lightman S. L. Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev. 1989 Jun;16(2):95–115. doi: 10.1016/0305-7372(89)90013-3. [DOI] [PubMed] [Google Scholar]
  12. Reubi J. C. Evidence for two somatostatin-14 receptor types in rat brain cortex. Neurosci Lett. 1984 Aug 31;49(3):259–263. doi: 10.1016/0304-3940(84)90299-4. [DOI] [PubMed] [Google Scholar]
  13. Reubi J. C., Maurer R. Autoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary. Neuroscience. 1985 Aug;15(4):1183–1193. doi: 10.1016/0306-4522(85)90261-1. [DOI] [PubMed] [Google Scholar]
  14. Reubi J. C., Maurer R. Different ionic requirements for somatostatin receptor subpopulations in the brain. Regul Pept. 1986 Jul;14(4):301–311. doi: 10.1016/0167-0115(86)90172-2. [DOI] [PubMed] [Google Scholar]
  15. Reubi J. C., Perrin M., Rivier J., Vale W. High affinity binding sites for somatostatin to rat pituitary. Biochem Biophys Res Commun. 1982 Apr 29;105(4):1538–1545. doi: 10.1016/0006-291x(82)90963-9. [DOI] [PubMed] [Google Scholar]
  16. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 1988 Dec 15;48(24 Pt 1):6977–6985. [PubMed] [Google Scholar]
  17. Shepherd J. J., Senator G. B. Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995. Lancet. 1986 Sep 6;2(8506):574–574. doi: 10.1016/s0140-6736(86)90139-x. [DOI] [PubMed] [Google Scholar]
  18. Sheppard M., Shapiro B., Pimstone B., Kronheim S., Berelowitz M., Gregory M. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab. 1979 Jan;48(1):50–53. doi: 10.1210/jcem-48-1-50. [DOI] [PubMed] [Google Scholar]
  19. Srikant C. B., Dahan A., Craig C. Receptor binding of somatostatin-14 and somatostatin-28 in rat brain: differential modulation by nucleotides and ions. Regul Pept. 1990 Feb 4;27(2):181–194. doi: 10.1016/0167-0115(90)90038-x. [DOI] [PubMed] [Google Scholar]
  20. Srikant C. B., Patel Y. C. Somatostatin analogs. Dissociation of brain receptor binding affinities and pituitary actions in the rat. Endocrinology. 1981 Jan;108(1):341–343. doi: 10.1210/endo-108-1-341. [DOI] [PubMed] [Google Scholar]
  21. Srikant C. B., Patel Y. C. Somatostatin receptors: identification and characterization in rat brain membranes. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3930–3934. doi: 10.1073/pnas.78.6.3930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Yamada Y., Post S. R., Wang K., Tager H. S., Bell G. I., Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251–255. doi: 10.1073/pnas.89.1.251. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES